Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
BTIG Biotechnology Conference 2022 (Hybrid)
Fireside Chat: A pre-recorded fireside chat will be available via the conference website starting August 8, 2022 at 9:00 AM ET.
2022 Wedbush PacGrow Healthcare Conference (Virtual)
Panel: A View to a Kill(er Cell) - Part 1
Panel date/time: Wednesday, August 10, 2022, 1:10pm ET
A live webcast and archived replay of the panel will be available on the investors section of www.vorbio.com.
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Media & Investors
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.36 |
| Daily Change: | -0.01 -0.73 |
| Daily Volume: | 224,980 |
| Market Cap: | US$169.370M |
January 08, 2025 December 27, 2024 September 05, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
